Roche Holding Ltd. (ROG) Given a CHF 260 Price Target at Morgan Stanley

Morgan Stanley set a CHF 260 price target on Roche Holding Ltd. (VTX:ROG) in a research note issued to investors on Friday. The firm currently has a neutral rating on the healthcare company’s stock.

Several other analysts have also weighed in on the company. Goldman Sachs Group, Inc. (The) set a CHF 325 price objective on Roche Holding and gave the company a buy rating in a research note on Monday, September 11th. Credit Suisse Group set a CHF 300 price objective on Roche Holding and gave the company a buy rating in a research note on Monday, September 11th. Citigroup Inc. reaffirmed a buy rating on shares of Roche Holding in a research note on Wednesday, July 5th. Societe Generale set a CHF 275 price objective on Roche Holding and gave the company a neutral rating in a research note on Thursday, June 29th. Finally, Baader Bank set a CHF 231 price objective on Roche Holding and gave the company a neutral rating in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. Roche Holding has a consensus rating of Hold and an average price target of CHF 267.73.

Shares of Roche Holding (ROG) traded up 0.08% during midday trading on Friday, hitting CHK 247.90. 881,442 shares of the stock traded hands. The stock has a 50 day moving average of CHK 244.39 and a 200 day moving average of CHK 251.55. Roche Holding has a 1-year low of CHK 218.30 and a 1-year high of CHK 273.00. The company has a market capitalization of CHK 211.52 billion and a P/E ratio of 22.01.

COPYRIGHT VIOLATION NOTICE: “Roche Holding Ltd. (ROG) Given a CHF 260 Price Target at Morgan Stanley” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/20

Several other analysts have also weighed in on the company. Goldman Sachs Group, Inc. (The) set a CHF 325 price objective on Roche Holding and gave the company a buy rating in a research note on Monday, September 11th. Credit Suisse Group set a CHF 300 price objective on Roche Holding and gave the company a buy rating in a research note on Monday, September 11th. Citigroup Inc. reaffirmed a buy rating on shares of Roche Holding in a research note on Wednesday, July 5th. Societe Generale set a CHF 275 price objective on Roche Holding and gave the company a neutral rating in a research note on Thursday, June 29th. Finally, Baader Bank set a CHF 231 price objective on Roche Holding and gave the company a neutral rating in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. Roche Holding has a consensus rating of Hold and an average price target of CHF 267.73.

Shares of Roche Holding (ROG) traded up 0.08% during midday trading on Friday, hitting CHK 247.90. 881,442 shares of the stock traded hands. The stock has a 50 day moving average of CHK 244.39 and a 200 day moving average of CHK 251.55. Roche Holding has a 1-year low of CHK 218.30 and a 1-year high of CHK 273.00. The company has a market capitalization of CHK 211.52 billion and a P/E ratio of 22.01.

COPYRIGHT VIOLATION NOTICE: “Roche Holding Ltd. (ROG) Given a CHF 260 Price Target at Morgan Stanley” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/07/roche-holding-ltd-rog-given-a-chf-260-price-target-at-morgan-stanley.html.

About Roche Holding

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche Holding (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply